Abstract Abnormal copy number of chromosomes, genes, or individual exons can have deleterious effects that lead to recognizable genetic disorders. Until recently, the traditional methods of karyotyping, fluorescence in situ hybridization, and rudimentary PCR-based assays were the only choices available to detect copy number abnormalities. The advent of chromosomal microarrays and nextgeneration sequencing has now dramatically improved our ability to detect deletions or duplications with superior resolution compared to that possible with previous methods. Each method has inherent properties and variations that provide advantages in detecting mutations in specific genomic environments, but those same properties can be limiting in other regions as well as in scalability. Improvements in bioinformatics algorithms predict a complete shift toward next-generation sequencing for detecting the entire range of copy number abnormali ties, although microarray and other technologies will continue to be useful as confirmatory tests and for investigating complex structural rearrangements and non-unique sequences.
Introduction
Copy number variation in the human genome can be associated with severe clinical disorders, or can represent a benign polymorphism [1 •• -3] . The methods to detect this variation have evolved from simple single-locus interrogations, initially, to genome-wide high-resolution surveys in recent years (Table 1) . Aneuploidy was perhaps the most commonly recognized form of copy number abnormality in the human genome with a clinical outcome, but studies in the past decade have made it evident that [1 kb submicroscopic deletions and duplications are frequent in our genome and now qualify as the most common form of copy number variation in humans [4] . The extent of copy number variation in the 100 bp-1 kb range remains poorly understood due to the absence of robust technologies to detect this variation on a whole genome scale. Larger copy number variants (CNVs) were initially characterized by fluorescence in situ hybridization and other methods, but detection of these CNVs genome-wide and en masse only occurred with the recent advent of high-resolution DNA microarrays. Similarly, deletions and duplications of small sequences within genes (e.g., exons) were initially investigated by Southern blot or quantitative PCR, but more sophisticated methods such as multiplex ligation-dependent amplification (MLPA) and exon-focused microarrays have brought significantly higher resolution and flexibility. We now recognize the entire gamut of copy number variation, from whole chromosomes to complete genes to individual exons, and each category is associated with a plethora of genetic disorders. Most methods for copy number detection are rigid and not scalable, preventing the development of a single platform for genome-wide and high-resolution analysis of copy number. While microarrays somewhat surpass this limitation, it is really exome and whole-genome sequencing that offer a robust remedy because of the single nucleotide resolution. However, unlike with previous methods, complicated algorithms are necessary for accurate copy number detection from next-generation sequencing (NGS) data. As exome and whole-genome sequencing become standard methods in clinical labs in the next 5 years, the algorithms to calculate copy number will improve significantly and leave other methods to be used for more specialized purposes, such as interrogating structural rearrangements and assessing copy number in complex sequences.
Traditional Cytogenetics
For the last 45 years karyotyping was the gold standard for studying chromosomes [5] . A relatively inexpensive method, karyotyping has been routinely used in postnatal and prenatal genetic testing to detect aneuploidies, translocations, inversions, supernumerary chromosomes, and large deletions and duplications. With some variation in the chromosome staining method used to identify the heteroand euchromatic bands, karyotyping has been valuable in addressing many concepts in classical cytogenetics, including the frequencies of aneuploidies, mechanisms of unbalanced rearrangements, and meiotic dispersal of abnormal chromosomes. Despite its significant contributions to clinical genetics, karyotyping is limited to detecting copy number changes that extend from approximately 5 Mb to the full length of a chromosome (Table 1) .
In some cases, traditional chromosomal analysis can detect copy number changes less than 5 Mb in size, dependent upon the karyotypic resolution and specific genomic location (e.g., the 17p11.2 deletion causing Smith-Magenis syndrome). However, it was not until fluorescence in situ hybridization (FISH) was developed that deletions or duplications in the range of 200 kb-5 Mb could be routinely investigated [5] . The basic concept behind FISH usage in clinical diagnostics is the hybridization of large DNA fragments (e.g., BAC clones) to chromosome preparations from cells isolated from a clinically affected individual to identify deletions, duplications, amplifications, or copy-neutral rearrangements. FISH can be used on cells in metaphase captured with appropriate cell culture treatments; this approach is sensitive for detecting deletions larger than 200 kb and for duplications larger than 1 Mb [6, 7] . FISH on cells in interphase is more suitable for duplications between 500 kb and 2 Mb, but these can be difficult to detect when they are in tandem. A modified protocol called fiber FISH can be used to detect small tandem duplications [8, 9] , but this is not typically available in clinical settings. Recent developments have replaced the large insert clones that are typically used as FISH probes with synthetic oligonucleotides, which provide advantages in terms of specificity and the number of targets [10 • 
FISH has a variety of important applications, including detecting recurrent CNVs associated with microdeletion syndromes, confirming array CGH findings and determining the nature of complex rearrangements (e.g., mapping unbalanced translocations or identifying marker chromosomes), and investigating genome-wide copy number changes. This last application is based on a modified method called spectral FISH that evolved from comparative genomic hybridization (CGH), an approach used to map all [20 Mb deletions and duplications in a clinically affected genome tested against a normal reference genome [11] . Spectral FISH and CGH have been largely used for research in cancer cytogenetics but did not find broad application in a clinical setting [12, 13] . However, CGH did provide the conceptual basis for a dramatic advance in genome-wide copy number detection based on DNA microarrays, described in detail in a later section.
Molecular PCR-Based Approaches
While aneuploidies and [200 kb microdeletions and duplications can be interrogated by cytogenetic methods, deletions or duplications that span a few hundred nucleotides to a few kilobases are amenable to study via a variety of molecular methods, including Southern blotting, quantitative PCR, MLPA, and digital droplet PCR (Table 1) . This review will not discuss Southern blotting since it is largely obsolete in clinical laboratories and restricted to very specialized purposes, such as confirming expanded triplet repeats. Readers are referred to previously published articles for more detail [14] . More recent technologies, such as molecular inversion probe assays (MIP), multiplex amplicon quantitation (MAQ), quantitative oligonucleotide ligation assay (qOLA), invader assay, and pyrosequencing, are now available and well-suited for analyzing small deletions, duplications, and even amplifications.
Quantitative real-time PCR (qPCR) has been widely used in research but less often in clinical settings. It was initially used for gene expression studies but was eventually adopted for assaying copy number in genomic DNA. There are variations of qPCR methods with commercially available kits, and one of the most robust involves a Taqman assay involving sequence-specific PCR primers and fluorescence-tagged hydrolysis probes using fluorescence resonance energy transfer (FRET) [15] . Briefly, a short hydrolysis probe with a fluorescent reporter dye on the 5 0 end and a quencher dye on the 3 0 end hybridizes to a target sequence. Subsequent PCR amplification with flanking primers cleaves the probe due to the 5 0 exonuclease activity of the Taq polymerase. Separation of the reporter and quencher causes activation of the reporter, which can be measured by a fluorescence-detecting instrument. Quantification of the template copy number is based on the number of PCR cycles (the C t value) required to bring the fluorescence to an arbitrary point within the exponential phase of amplification. The C t value of the test sample is determined relative to that of a control sample for which the copy number is known. While real-time qPCR has the advantage of being used for virtually any gene in the genome, it is laborious because it requires careful primer selection, optimization of primers over a standard curve, and testing of multiple controls to ensure reproducibility.
MLPA is a widely used technology to evaluate copy number at up to forty genomic loci [16] . The method is based on using two probes that anneal to specific sequences adjacent to each other. In the subsequent step, DNA ligase joins the two probes if the hybridization is perfect and there is no mismatch at the end of each probe, thereby creating one single large fragment. Each probe consists of two parts-a sequence complementary to a target and a universal primer sequence. Amplification of ligated products with a single dye-labeled primer set and subsequent capillary electrophoresis provides copy number data. The number of ligation products serves as a direct measure of the copy number of the target sequence. Using probes of different lengths to separate products during electrophoresis allows multiplexing to simultaneously interrogate multiple loci within the same gene as well as in different genes. A modified MLPA protocol is also available to detect differentially methylated sequences, enabling diagnosis of imprinting disorders such as Prader-Willi and Angelman syndromes [17] .
A modification of traditional qPCR, digital droplet PCR is a recent development that allows more sensitive quantitation of template DNA. Where traditional PCR is sometimes unreliable for quantitation because it can be compromised by low template concentrations, non-reproducible amplification at the exponential phase, and inconsistency in the number of cycles required to reach the plateau phase, digital PCR circumvents these limitations because it occurs in individual compartments that each contain a single template molecule. Emulsion droplets are one example of these compartments, and several commercially available kits based on this technology are available. Integration of Taqman chemistry into the digital droplet PCR protocol provides a sensitive platform for assaying copy number at predetermined targets [18 • ]. The concentrations of amplified product are calculated based on the number of fluorescent droplets produced by primers at the target locus and compared to that produced by primers at a reference locus.
MIPs offer another method to evaluate copy number at specific loci [19] . The technology is based on using a pair of probes that hybridize to a target sequence and are separated by a single nucleotide, in the same manner as MLPA probes. However, MIP probes also contain other sequences to allow circularization of the perfectly hybridized probe pair and subsequent PCR amplification. The amplified products are hybridized to single nucleotide polymorphisms (SNP) microarrays to detect the genotype and copy number of target loci. The advantages of this technology include high specificity, low template DNA amount, a large dynamic range to accurately count up to 50 copies, and scalability across many targets. MIP has also been adapted for obtaining sequence data [20] .
Less commonly used molecular methods for copy number detection include MAQ, qOLA, invader assay, and pyrosequencing. MAQ is a multiplex PCR assay with isothermal primers that amplify up to 50 targets from both test loci and copy number-stable control loci in a single reaction [21] [22] [23] . The copy number is determined by electrophoresis and fluorescence-based quantitation of amplified products from the test loci in relation to those from the control loci. qOLA is a variation of MLPA and has been used to quantify zero to six copies of target loci and can also be used to genotype alleles [24] [25] [26] . Different targets are identified by varying amplicon lengths. The Invader assay is a commercially available technology that uses a probe containing a target-specific region and a 5 0 flap sequence. An invader oligonucleotide that binds the sequence adjacent to the target and has a one-base overlap with the probe elongates in a PCR and cleaves the 5 0 flap sequence. The released flap fragment binds as an invader oligo on a synthetic target that contains a FRET probe. Cleavage of the FRET probe releases a fluorescent signal that is quantified. The Invader assay is highly scalable and specific, and can be used to interrogate multiple loci simultaneously and also genotype target alleles [27, 28] . Lastly, pyrosequencing is a technology based on detecting released pyrophosphates that are used to generate ATP for a luciferase reaction. Pyrosequencing can be used to assay for specific single nucleotides but also quantify target loci up to six copies [29] [30] [31] . However, since each of these methods require careful and laborious probe and primer optimization and calibration of reaction conditions across many control samples, they are not routinely used in the clinical setting.
DNA Microarrays
Initial phases of the Human Genome Project focused on building physical maps using large insert clones, such as bacterial artificial chromosomes (BACs). This was essential to not only create a map to position known genomic landmarks but also to use the clones themselves as templates for sequencing. The availability of these clones, the completion of the human genome sequence, and the development of glass surface-based nucleotide arrays together led to the first DNA microarrays that could be used to evaluate copy number of sequences in the human genome [32] . Taking a cue from traditional CGH used in cancer cytogenetics, BAC arrays were deployed in clinical settings to detect copy number abnormalities first at specific targets but eventually across the whole genome [33, 34] . DNA microarray CGH (array CGH) technology essentially compares copy number at specific loci in a patient sample in relation to the copy number in a cohybridized and differently labeled reference sample. Unlike traditional CGH, which hybridizes labeled test and reference genomes to a metaphase cell spread, array CGH utilizes a set of DNA fragments on a glass surface. The singular advantage of array CGH is the ability to select which portions of the genome to target and thereby define the resolution of detection. The methodology has been described in detail elsewhere [13, 35] .
While BAC arrays set the stage for whole genome copy number analysis in clinical diagnostics [33, 34] , it was oligonucleotide arrays that firmly established this technology as the standard for evaluating the human genome for CNVs [36 • , 37] . Oligonucleotide arrays provide superior resolution and quality when compared to BAC arrays and have been used extensively in the last 5 years to generate a high-resolution map of pathogenic and benign copy number variation in the human genome [2, 3, [38] [39] [40] . BAC microarrays offer resolution down to 150-250 kb whereas oligonucleotide arrays refine that resolution to less than 1 kb.
The availability of CGH oligonucleotide-based microarrays also enabled copy number analysis of single exons and genes, essentially replacing MLPA and qPCR, because the array offered better resolution across every exon and data from a large numbers of genes [41-43 • ]. These ultra high-resolution arrays can detect deletions as small as 200 bp at virtually every exon of targeted genes. This same methodology can be expanded to cover the entire exome to complement whole genome or exome sequencing and will likely be available for broad clinical use in the near future.
Oligonucleotide microarrays with probes containing SNPs offer an alternative to CGH microarrays [44 • , 45] . SNP microarrays were initially developed to genotype specific alleles for association studies and similar investigations, but evolved into ones that can survey genotypes as well as copy number [46, 47] . This is accomplished by qualitatively detecting which probe is bound by labeled DNA fragments from the tested genome (hence identifying the alleles in that genome) and also quantitating the fluorescence of the bound DNA. Probes representing each allele at a polymorphic locus are represented on the microarray. A reference genome is not co-hybridized. Unlike CGH arrays, because SNP arrays provide not only copy number data but also genotype information, they allow efficient detection of long stretches of homozygosity that can indicate uniparental disomy or identity by descent. The methodology and the advantages of SNP microarrays are described in detail elsewhere [45, 48] .
Multiplex amplifiable probe hybridization (MAPH) is a technology that utilizes a set of probes that are hybridized to a test genome on a nylon filter and then recovered for quantitative amplification. A more robust version of this method, replacing gel electrophoresis in the last steps with oligonucleotide microarrays, significantly increases the number of targets assayed [49] . MAPH provides a much higher signal-to-noise ratio because of the specific probe targeting and PCR amplification instead of a whole genome hybridization as performed in microarray CGH, and therefore can be used even within complex genomic sequences that are usually difficult to assay by other methods.
Next-Generation Sequencing
While DNA microarray technologies have shown considerable promise in high-throughput and cost-efficient diagnostic studies, their ability to accurately determine the length of an aberration can be limited by the density of oligonucleotide probes or SNPs within a target region [50] . The robustness of any CNV detection methodology or analysis algorithm not only lies in accurate delineation of the breakpoints and precise estimation of size but also in estimating the absolute change in copy number of a genomic region and delineating different classes of variants. NGS offers the advantage of a whole genome approach and the ultimate resolution of a single nucleotide. Sophisticated computational algorithms are necessary to extract copy number data from NGS data by aligning sequence reads against a reference genome for comparison. Algorithms to detect CNVs were first developed for readpairs from BAC clone end sequences generated from the breast cancer cell line MCF-7 [51] , and subsequently adapted to detect variation from fosmid paired-end sequences and from next generation paired-end sequence data [52, 53] . These algorithms were developed to assess genome-wide copy number changes using whole-genome sequencing data. It is important to note that these algorithms are confounded by exome data sets because of the hybridization biases and uneven coverage throughout the genome.
The read-pair approach takes into account the span and orientation of sequence reads in comparison to a reference genome. This approach is based on the principle of identifying discordant signatures of sequence content and orientation, which may be diagnostic of different patterns of structural variation. Read pairs whose sequenced ends anchor to the reference genome are considered discordant if the mapping distance between them varies from the expected length [54] . The accuracy of the read-pair approach depends on the read length, insert size, and physical coverage of the genome. This approach also allows for the detection of inversions (discordant for orientation) in addition to deletions and duplications. Readdepth approaches estimate copy number by quantifying the mapping depth of sequence reads that are assumed to be in a random Poisson distribution. Duplications and deletions are discovered based on the deviation (higher or lower depth) compared to known diploid regions of the genome. Modifications to this strategy, including incorporation of robust statistical parameters and single unique nucleotide identifiers, have improved the sensitivity and accuracy of CNV detection. The read-depth approach, however, cannot detect inversions and tandem duplications. Statistical and algorithmic modifications to the read-depth approach have been used to normalize depth-of-coverage counts from exome sequencing data. For example, singular value decomposition (SVD) normalization for CoNIFER [55] , principle component analysis and hidden Markov model for XHMM [56] , Geary-Hinkley transformation for ExomeCNV [57] , or circular binary segmentation algorithm for VarScan2 [58] , have been added to read-depth data for improved CNV calling. Split-read approaches were devised to detect exact breakpoint locations based on the broken reads or gaps among the reads, and can also be extended to identify mobile-element insertions, paralogous repeats, and pseudogenes [59] . For example, Karakoc et al. recently devised an algorithm based on split reads to discover smaller insertion-deletions from exome sequencing data from individuals with autism [60] . Optimum use of this method requires longer reads and higher coverage of the genome. Moreover, instead of mapping reads to a reference, de novo assembly of sequences would provide a more accurate estimate of copy, content, and structure of genomic regions [50, 61 • ]. However, this approach requires long and high-quality sequence reads. While local sequence assemblies from fosmid clones have been systematically used to discover CNVs, sequences are now assembled de novo as well as locally and then compared to a high-quality reference genome.
Despite the promise held by NGS-based copy number detection methods, current algorithms are limited by the fact that the sensitivity and specificity vary with each approach and a significant fraction of variants are unique to a specific approach [50] . While the read-depth approach can detect absolute copy number using single unique nucleotide identifiers in duplicated regions of the genome, it cannot resolve breakpoints accurately and cannot identify structural differences such as tandem duplications or inversions. Read-pair and split-read approaches do not reliably resolve copies within repetitive regions. In addition, these strategies are not sufficiently powered to detect CNVs generated due to a potential fork-stalling template switching mechanism or translocation events [62] . Recent studies have also shown that pair-wise comparisons of assembled genomes can be biased against repetitive or multi-copy regions [50] . One solution to increase the sensitivity and specificity of CNV detection is to combine computational methodologies. Algorithms that combine two orthogonal approaches for better CNV detection are now available (e.g., SPANNER [63] , CNVer [64] , and Genome STRiP [65] ). Only generation of longer sequence reads with adequate genomic coverage will mitigate most limitations associated with detection of CNVs from NGS data.
General Considerations
There are several factors that impact all copy number detection methods (Table 1) . For instance, an important consideration is the ability to avoid pseudogenes with high homology to the target of interest. There are more than 10,000 pseudogene sequences in the human genome and these exist as either processed or non-processed (segmental duplication) sequences [66] . DNA microarrays are not suitable for assaying copy number at loci that have pseudogene copies elsewhere because it is difficult to discern the location of deleted or duplicated material. NGS based on capture methods is also limited in its ability to quantify copy number at loci that have one or more homologous sequences scattered in the genome. Methods that can take advantage of sequence differences between the functional gene and its pseudogene copy are typically very effective at detecting copy number changes at the target locus (functional gene), and these include MLPA, MIP, qOLA, invader assay, or pyrosequencing.
A second consideration for copy number detection methods is scalability-the number of target loci that can be simultaneously interrogated (Table 1) . NGS and DNA microarrays are of course the best options for large numbers of targets. NGS offers the ultimate solution for scalability, but even a single microarray design is sufficient to target the whole genome and even include the mitochondrial genome. Even with exon-focused microarrays, the whole exome can be targeted on a single high-resolution oligonucleotide array (SA, unpublished data). Most PCRbased molecular methods can only interrogate anywhere from one to forty targets and are appropriate for frequently used clinical tests aimed at a limited number of loci.
The resolution of detection is a consideration mainly for microarrays since the other methods are essentially designed with a known target and NGS has single nucleotide-level resolution. Oligonucleotide CGH microarrays can detect deletions and duplications from 200 bp to the full length of a chromosome. SNP microarrays have less resolution (10-15 kb at a minimum) but can identify individual nucleotide variation qualitatively. Molecular methods in general can detect deletions or duplications that are 100 bp or larger and contain the target sequence for the probes or primers used in the assay, and some of these can also qualitatively identify single nucleotides.
The dynamic range of detectable copy number varies among the described methods. While all of them can distinguish between zero and four copies, some are limited in their abilities to detect amplifications of DNA material (present in four to many tens of copies). Interphase FISH is used to qualitatively detect oncogene amplifications in cancer, such as HER-2 amplifications in breast cancer [67] . However, detecting large numbers of a genomic locus quantitatively is challenging and only some methods are capable of this, such as MIP (Table 1) .
Finally, it is important to consider which method is appropriate for specific clinical contexts. Each method has advantages as well as limitations that define its suitability for use in diagnostic testing. For example, the traditional cytogenetic methods are more appropriate and sensitive for investigating balanced rearrangements and for detecting mosaicism. Similarly, when results are needed quickly, as in prenatal testing, locus-specific FISH and PCR-based methods are better suited compared to NGS and array CGH. However, once the locus of interest narrows to a small region or even a single gene, molecular methods rather than FISH or karyotyping are required to obtain the necessary data, such as genotype, intragenic deletions, and submicroscopic multi-gene CNVs. In contrast, high-resolution surveys of the whole genome call for DNA microarrays or NGS-based approaches to address complex genetic conditions involving developmental delay, intellectual disability, and congenital anomalies [36 • ]. Therefore, while the availability of a myriad copy number detection methods provides the flexibility to address a wide range of situations in genetic testing, the appropriate methods have to be chosen carefully depending on the clinical context.
Conclusions
Copy number detection has become easier, more accurate, and highly scalable. With methods such as NGS, microarrays, and MLPA, a wide variety of needs can be met in a clinical testing environment. While some disorders, such as holoprosencephaly or aniridia, require a simpler method with limited targets but high specificity, other disorders that are more genetically heterogeneous have to be addressed at a whole genome scale. With rapidly dropping costs, increasing efficiency, and more accurate and reproducible data, NGS promises to replace most copy number methods and restrict them to specialized needs, such as determining the structural nature of chromosomal rearrangements, surveying complex sequences, or providing a high throughput option for a small target gene list. The transition to NGSbased copy number detection is largely dependent on the development of robust algorithms and end-user software, and many efforts are underway in both the public and private sectors to address this need. Identifying deletions or duplications from a the whole genome scale and down to a single nucleotide resolution, and analysis of thousands of individuals in the coming years, will significantly complement sequence variation data and contribute to our understanding of the magnitude of all variation in our genome.
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